Neurorehabilitation Devices Market Is Estimated To Reach USD 3.2 Billion By 2024

Around 1 billion people are suffering from neurological disorders across the globe. These neurological disorders are resulting in increased movement disabilities. The increasing prevalence of movement disability, attributed to various neurological disorders (multiple sclerosis, stroke, etc) along with need for comprehensive management is the key factors driving the market growth.

Every year around 15 million people suffer from stroke globally, of which 5 million people are affected by permanent disability. Each year Multiple sclerosis and Parkinson’s disease affect 2.5 million and 10 million patients respectively worldwide. The increasing prevalence and incidence rates of neurological disorders create a huge demand for neurorehab devices, as they ensure simplification of routine tasks for the disabled patients by reducing their dependency on others.

Furthermore, the rising awareness of neurorehab services among the care providers is contributing to the increasing adoption of these devices. In addition, consistent technological advancements are leading to introduction and commercialization of novel products in this sector. Majority of the manufacturers and distributors of neurorehab platforms are headquartered in North America region. North America dominates the market followed by Europe attributed to the rising awareness and increased adoption of novel technologies in these regions. Asia Pacific is growing at the highest CAGR among all the regions due to increasing target population and improving healthcare infrastructure.

Despite fluctuating economic conditions across different geographical regions coupled with the respective regulatory pressures, the companies offering neurorehab devices and services are exhibiting adaptability and efficacy. Some of the key market players are Bioness, Inc., Ectron Ltd., Hocoma AG, Medtronic, and Tyromotion. Collaborations for novel product development and strengthening of distribution networks constitute some of the strategic initiatives implemented by key players. For instance, Ectron Ltd. has collaborated with Bioness, Inc. and Tyromotion for distribution of their products across different geographical regions.

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• Neurorobotics is expected to be one of the most lucrative segments in the coming years owing to the high availability of exoskeletons and prosthetics targeted for treating movement disabilities. Bioness, Inc. and Hocoma AG are few of the key manufacturers of exoskeletons and prosthetics.
•  Consistent technological sophistications in brain stimulations and machine learning brain-computer interface segment is expected to develop tremendously.
• Non invasive stimulators have the potential to modulate brain plasticity. In February 2016, USFDA approved Medtronic’s brain stimulation therapy in the treatment of Parkinson’s disease.

Click Here For Access Full Report :  https://goo.gl/k5jP9h

Clinical Trial Management System (CTMS) Market Growth Is Expected To Reach USD 2.2 Billion By 2024

Rising research activities and increasing complexity in data management for multiple verticals such as pharmaceutical and biotechnology are anticipated to present the clinical trial management system market with lucrative opportunities over the forecast period. These systems are capable for speeding up the research activity along with cost containment which is crucial for pharmaceutical companies that invest a lot on R&D innovation.

The present business scenario is witnessing rapid changes in the market place and consumer preferences are pushing the players to innovate and generate better performing products at a faster rate, in order to sustain the competition. Owing to the aforementioned reason, CTMS are designed in way that requires minimal documentation by clinical trial professionals avoids unnecessary & repeat testing and facilitates easy payment management. This at the end makes the whole process faster and reduces the time to market.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Enterprise based CTMS segment is expected to hold maximum shares and witness the fastest growth over the forecast period. Enterprise system dominated owing to their convenience and multiple user access. For instance, the enterprise CTMS currently being used in the University of Minnesota which offers implementation of a variety of functions via its core module.
• Cloud-based delivery mode is expected to witness the fastest growth and contribute over 15.0% share by 2024. Increasing popularity leading to higher adoption by end-users for cloud-based CTMS is the vital impact rendering driver.
• Pharmaceutical & biotechnology firms held about 40.0% share in 2025 and is expected to contribute highest revenue over the forecast period. Extensive pipeline and rising affinity towards collaborative research over the next decade is predicted to boost market growth.
• Asia Pacific is projected to drive the market growth and provide numerous opportunities to industry players. The efforts by government officials and research industry towards improving infrastructure, rising number of research studies and digitalization coupled with centralization of the management systems are promoting growth of CTMS market over the forecast period.
• The market is highly fragmented with numerous budding small scale companies. Few of the participants include; PARAXEL International Corporation, DATATRAK, Guger Technologies, Forte Research Systems Inc., MedNet Solutions, Bioclinica, Medidata Solutions Inc., and Oracle Corporation.

Click Here For Access Full Report : https://goo.gl/UhnkhW

Antibiotics Market Growth Is Expected To Reach USD 57.0 Billion By 2024

Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth.

More than 15.0% of the deaths, in children below the age of five, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015. Similar to tuberculosis, the highest prevalence of the disease is identified to be in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one third of the infected population, thereby increasing the disease burden.

Government reforms specific to antibiotics such as the Generating Antibiotics Incentives Now (GAIN) Act in the U.S. are projected to help market growth over the forecast period. This further expected facilitate development of advanced drugs.

On the contrary, uncertain regulatory policies are likely to hinder the growth of this vertical impacting market growth significantly. In 2013, the U.S. FDA revised the guidance for registration trials for drugs used in the treatment of acute bacterial skin and skin structure infections. The guidance states the use of short term measures of anti-infective efficacy (percent reduction in lesion size at 48 to 72 hours) as opposed to long term measures such as resolution of infection at 10-14 days, which is termed as Test to Cure or TOC.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• Antibiotic segment including tetracyclines, imidazoles, lincosamides and monoclonal antibodies held commanding share in 2015 and are also anticipated to grow at a lucrative growth rate over the forecast period
• Development of monoclonal antibodies for antibiotic resistant microorganism is key highlight of this segment. Increasing incidences of pneumonia, blood stream infections, and urinary tract infections (UTI) are anticipated to foster the usage of carbapenems class of antibiotics.
• Cell wall synthesis inhibitors dominated the mechanism outlook in 2015. Majority of the antibiotics such as penicillins, cephalosporins and carbapenems forms the cell wall synthesis inhibitor class.
• RNA synthesis inhibitors as well as folic acid synthesis inhibitors are anticipated to witness healthy growth over the forecast period. Development of several antiviral drugs which inhibit transcription and reverse transcription process are anticipated to support the growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have wide application scope.
• Asia Pacific on account of huge population base, high prevalence of infectious diseases, regulation reforms and greater usage of generic medicine held commanding share in 2015.
• Latin America, especially Brazil with strong growth in pharmaceutical sector is also projected to exhibit remunerative growth. Outbreak of certain viruses such as Ebola in African region also contributed towards the significant growth of MEA region.
• Some of the key players in this vertical are Pfizer, Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company and Astellas Pharma, Inc.

Click Here For Access Full Report : https://goo.gl/7zeEFA

U.S. Clinical Oncology Next Generation Sequencing Market Is Anticipated To Reach USD 1.53 Billion By 2024

Application of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of cancer.

Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost growth of this vertical throughout the forecast period.

Moreover, exponentially decreasing costs for sequencing have also spurred the demand for NGS platform in clinical oncology research as whole genome analysis has become affordable even by the smaller R&D entities. In addition, high competition amongst prominent market players to enhance their share in the market is also expected to translate into increased revenues generated by these companies as a result.

View summary of this report, Click Here

Further key findings from the report suggest:

• Out of the different technologies offered by NGS platforms, targeted sequencing & resequencing accounted for the largest share owing to the fact that it enables study of changes in diseases at molecular level, & analyze the underlying modifications in the genetic sequence to investigate epigenomics of cancer, thus enhancing demand for more advancement in targeted sequencing tools.

• Workflow associated with genomic sequencing is expected to witness lucrative progress as a result of variation in platforms provided by prominent market players with respect to amount of DNA sequenced per cycle, read length, and runtime. Furthermore, data analysis of raw sequence data thus obtained, is the most critical step in the workflow of NGS, and is thus anticipated to experience immense growth in coming years as a consequence of abundance of data generated post sequencing.

• Adoption of high throughput sequencing platform by clinical sector is observed to be more promising for NGS based oncology research market as a consequence of usage of NGS in cancer research and more specifically in discovery of new cancer related genes, tumor heterogeneity, and identification of alterations that are contributive in tumorogenesis

• Key players operating in this industry include Illumina Inc., Roche, Agilent Technologies, Knome Incorporated. Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd, Macrogen Inc., Life technologies Corp, DNASTAR Inc, Exosome Diagnostics, Biomatters Ltd, CLC Bio, BGI, Qiagen NV, Perkin Elmer, Incorporated, Pacific Bioscience, Inc, Partek, Inc, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences and Myriad Genetics and they are actively engaged in manufacturing and commercialization of innovative bioinformatics algorithms as demonstrated by the increasingly growing number of partnerships between prominent players and emerging players.

• For instance, In February 2016, Thermo Fisher collaborated with Invivoscribe Technologies, Inc for the development of NGS based, in vitro diagnostic (IVD) oncology tests on Ion PGM Dx System which is further anticipated to accelerate growth of the company in near future. Similarly, in June 2016, Thermo Fisher supported enhancement and commercialization of clinical research assay and in vitro diagnostics using NGS technology launched the Ion Torrent Developers Alliance Program.

Click Here For Access Full Report : https://goo.gl/cUhuFn

Global Biological Implant Market Is Anticipated To Reach USD 9.8 Billion By 2024

Biological implant market is driven by rise in adoption of grafts and organ substitutes for reconstructive surgeries for various clinical applications such as cardiovascular, orthopedic and other soft tissue repair. The main challenge associated with the use of these products is to incorporate such a material that can specifically adapt to the biology of the surrounding environment in order to accelerate regeneration and repair. To overcome this challenge, research endeavors are carried out in order to develop such devices from biological source thus affecting industrial growth in the coming years.

Modification in the process of composite grafting is expected to play a crucial role in tackling reimplantation of amputated fingertips by bringing development in the overall process of grafting. Moreover, rising competition amongst key participants operating in this market is one of the high impact rendering factors to accelerate the growth.

View summary of this report, Click Here 

Further key findings from the report suggest:

• Depending upon the source or donor of grafts, products offered can be categorized into autograft, allografts, and xenografts. Xenografts dominated the revenue share in 2015 with a revenue share of over 50%. However, allografts are expected to witness the fastest growth owing to the fact that they are derived from same species and produce considerably less chances of foreign immune reaction, thereby influencing adoption rate.
• Biological implants serve various application domains which include cardiovascular, orthopedic, and other soft tissue implants. Soft tissue products accounted for the largest share in 2015 as a result of higher usage of the products in the field of dentistry. Even though cardiovascular implants accounted for lowest penetration in the current scenario, demand for cardiovascular stents and valves obtained from biological source is expected to expand, consequently boosting revenue generation from this segment.
• Amongst surgical and injectable mode of administration, surgical mode is estimated to hold the larger share, as a consequence of availability of several products administered via this route. Introduction of minimally invasive techniques for surgical incorporation of grafts is also one of the significant factors propelling growth in this segment.
• North America dominated the market with a revenue share of 50% due to widespread presence of participants coupled with high aesthetic and healthcare awareness levels amongst the population in this region.
• Asia Pacific is estimated to exhibit the fastest growth in the coming years due to presence of the target population and rapidly improving health care infrastructure which is attributed to drive the demand for tissue engineered products and biological implants.
• Major players operating in this industry include Medtronic, NuVasive, Inc, Stryker Corporation, Conmed Corporation, CryoLife, Edwards LifeSciences Corporation, Acelity, Integra LifeSciences Corporation, Allergan Plc, RTI Surgical, IOP Ophthalmics, Organogenesis Inc, BioPolymer GmbH & Co. KG, Osiris Therapeutics, Baxter International, Vericel, Aplhatec Spine Inc, Maxigen Biotech Inc, Auto Tissue Berlin GmbH, MiMedx Group, Inc., Biotissue Technologies,
• These players are undertaking different business strategies to boost their respective penetration and enhance market presence. These strategies include novel product developments and geographic expansion by involving in collaborative activities in order to grab the larger share of revenue. For instance, in April 2016, Stryker Corporation acquired Stanmore Implants Worldwide Limited which is expected to enable the company to provide differentiated technologies to orthopedic oncology surgeons, thus propelling growth over the forecast period.

Click Here For Access Full Report : https://goo.gl/FoKJKV

Automated Dispensing Machine Market Is Expected To Reach A Value of USD 5.5 Billion By 2024

The growing pressure on the pharmaceuticals due to reimbursement reduction and rapidly growing drug prices leads to inefficient supply chain and inventory management. The growing demand for automated systems, such as RFID cabinet and barcodes, facilitates real-time inventory and stock management, which is one of the pivotal factors expected to drive the market in the coming years.

Furthermore, the increase in global geriatric population and prevalence of various chronic diseases, as well as high rates of hospitalization are some of the factors increasing the burden on pharmacy of hospitals and retail drug stores. Upsurge in number of prescriptions and lack of skilled pharmacist are also few factors expected to boost automation in the medication dispensing system.

There is increasing demand for technologically advanced medication dispensing systems to mitigate long waiting hours for stock replenishment and drug mismanagement, which is one of the crucial factors expected to drive the usage rate of pharmacy automation system, such dispensing, storage, and retrieval. Based on the 2011 ASHP national survey of pharmacy practice in hospital settings, it was stated that approximately 89% of the hospitals are using automated dispensing cabinets and over 10% of the hospitals are using robots.

According to a survey conducted by Society of Actuaries, it was found that measurable medication errors cost USD 20 billion to the U.S. economy, while majority of these errors could have been easily avoided. Increase in medication dispensing errors is a significant factor driving the number of adverse drug reactions, which may lead to severe deterioration of the patient’s health and may also lead to death; this is expected to drive the demand in the coming years. For instance, in the U.S., data published by the Institute of Medicine states that around 7,000 deaths each year can be attributed to medication errors.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• The inpatient segment is the leading application segment and occupies the largest share of 74.4% in 2015. Increasing cases of hospitalization coupled with occurrence of large number of medication errors contribute to the growth of this segment. The outpatient segment is expected to be the fastest growing segment during the forecast period with a CAGR of 8.2%.
• The hospitals’ segment is the largest, having a share of around 56.1% in 2015. Retail drug stores and pharmacies are expected to be the fastest growing segment during the forecast period with a CAGR of 7.8%.
• In 2015, the centralized pharmacy segment was the largest operations segment and occupied a share of around 63.4%. The decentralized pharmacy is expected to be the fastest growing segment during the forecast period, with a CAGR of 8.5%.
• In 2015, North America held majority of market share of over 53.8% in global automated dispensing machines market. Increasing medication errors and rising demand for the overall reduction in operational cost by streamlining medication dispensing processes are few key factors attributed to the regions high market share.
• Some of the key market players are Omnicell, Inc.; Becton, Dickinson & Co; Baxter; Swisslog; Parata Systems; AmerisourceBergen Corporation. The other key competitors in the market include Pearson Medical Technologies; Script Pro LLC; and Capsa Solutions.
• Click Here For Access Full Report : https://goo.gl/gzwq8Y

Genitourinary Drugs Market Is Expected To Reach USD 29.7 Billion By 2024

This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.

In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.

Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• Prostate cancer held the largest share of the indication segment in 2015 owing to the rising global incidence of the condition. In addition, advances in proteomics technology and improved screening and diagnostic procedures are presumed to be responsible for the dominant share. 

• Other products segment captured the majority share of 44.8% in the application segment in 2015. This is attributed to the numerous products launched by the major market players, which is responsible in widening the growth platform. For instance, in January 2016, ProstaPlast presented transdermal urological plasters in Europe, which demonstrated its clinical efficacy in reducing urinary problems in majority of the patients.

• In 2015, North America dominated the global genitourinary drugs vertical with a share of over 42.6%. The dominant share is attributable to the high disease burden present in this region, thus driving the inclination of researchers and healthcare professionals toward advanced formulation technologies, which is anticipated to widen the growth scope for this sector.

• Asia Pacific is expected to witness a lucrative CAGR of over 5.6% during the forecast period. The exponential growth rate can be attributed to the rising healthcare spending and the improving infrastructure quality of clinical research and manufacturing facilities owing to the initiatives of the key vertical players.

• The prominent participants are employing new product development and collaborative strategies to capture greater market share and increase their presence in this sector. For instance, in March 2015, Novartis AG further enhanced its cancer immunotherapy research initiative through collaboration with Aduro Biotech to increase its activities toward discovery and development in next generation cancer immunotherapy.

Click Here For Access Full Report : https://goo.gl/rftIj3

•